1,346
Views
30
CrossRef citations to date
0
Altmetric
Editorial

Targeting the leptin receptor: a potential new mode of treatment for breast cancer

&
Pages 1147-1150 | Published online: 10 Jan 2014
 

Financial & competing interests disclosure

The authors are inventors on a patent application covering peptide Allo-aca and analogs for the treatment of various cancer, arthritis and autoimmune disease forms. The patent is owned by Temple University and currently not licensed to any entity, although Peptherx, Inc., a biotechnology company founded by the authors, has a temporary option for the technology. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.